Dan Leonard
Stock Analyst at UBS
(4.02)
# 574
Out of 5,049 analysts
304
Total ratings
56.98%
Success rate
9.3%
Average return
Main Sectors:
Stocks Rated by Dan Leonard
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| GH Guardant Health | Maintains: Buy | $80 → $110 | $97.79 | +12.49% | 11 | Oct 30, 2025 | |
| IQV IQVIA Holdings | Maintains: Buy | $225 → $250 | $212.91 | +17.42% | 17 | Oct 29, 2025 | |
| TMO Thermo Fisher Scientific | Maintains: Neutral | $500 → $590 | $566.84 | +4.09% | 18 | Oct 23, 2025 | |
| A Agilent Technologies | Upgrades: Buy | $130 → $170 | $147.58 | +15.19% | 22 | Oct 8, 2025 | |
| TXG 10x Genomics | Maintains: Neutral | $12 → $13 | $13.79 | -5.73% | 6 | Aug 8, 2025 | |
| EXAS Exact Sciences | Maintains: Neutral | $61 → $53 | $72.75 | -27.15% | 10 | Aug 7, 2025 | |
| CERT Certara | Maintains: Buy | $18 → $15 | $11.73 | +27.88% | 10 | Aug 7, 2025 | |
| MEDP Medpace Holdings | Downgrades: Sell | $300 → $305 | $593.76 | -48.63% | 2 | Jul 29, 2025 | |
| DHR Danaher | Maintains: Buy | $240 → $225 | $215.15 | +4.58% | 18 | Jul 23, 2025 | |
| MTD Mettler-Toledo International | Upgrades: Buy | $1,530 → $1,350 | $1,428.90 | -5.52% | 9 | May 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $95 → $70 | $62.42 | +12.14% | 11 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $57 → $45 | $40.55 | +10.97% | 11 | May 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $355 → $310 | $313.63 | -1.16% | 20 | May 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $355 → $310 | $315.34 | -1.69% | 20 | May 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $145 → $115 | $93.89 | +22.48% | 2 | May 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $122 → $99 | $90.66 | +9.20% | 1 | Apr 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $29 → $25 | $11.74 | +113.04% | 7 | Jan 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $250 → $185 | $178.92 | +3.40% | 6 | Jan 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $7 → $9 | $9.09 | -0.99% | 2 | Oct 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $35 | $22.81 | +53.44% | 4 | Dec 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $225 → $200 | $119.34 | +67.59% | 16 | Aug 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $14 → $11 | $2.93 | +275.43% | 6 | Aug 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $70 | $202.65 | -65.46% | 7 | Aug 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Underperform | $7 | $17.24 | -59.38% | 2 | Feb 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $345 | $379.56 | -9.11% | 12 | Aug 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $260 | $168.32 | +54.47% | 5 | Aug 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $160 → $145 | $176.71 | -17.94% | 10 | Feb 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $95 → $90 | $74.22 | +21.26% | 12 | Feb 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $62 → $64 | $45.66 | +39.40% | 3 | Dec 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $330 → $340 | $254.00 | +33.86% | 11 | Dec 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $24 | $24.67 | -2.72% | 1 | Aug 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $45 → $35 | $6.74 | +419.29% | 12 | Aug 14, 2019 |
Guardant Health
Oct 30, 2025
Maintains: Buy
Price Target: $80 → $110
Current: $97.79
Upside: +12.49%
IQVIA Holdings
Oct 29, 2025
Maintains: Buy
Price Target: $225 → $250
Current: $212.91
Upside: +17.42%
Thermo Fisher Scientific
Oct 23, 2025
Maintains: Neutral
Price Target: $500 → $590
Current: $566.84
Upside: +4.09%
Agilent Technologies
Oct 8, 2025
Upgrades: Buy
Price Target: $130 → $170
Current: $147.58
Upside: +15.19%
10x Genomics
Aug 8, 2025
Maintains: Neutral
Price Target: $12 → $13
Current: $13.79
Upside: -5.73%
Exact Sciences
Aug 7, 2025
Maintains: Neutral
Price Target: $61 → $53
Current: $72.75
Upside: -27.15%
Certara
Aug 7, 2025
Maintains: Buy
Price Target: $18 → $15
Current: $11.73
Upside: +27.88%
Medpace Holdings
Jul 29, 2025
Downgrades: Sell
Price Target: $300 → $305
Current: $593.76
Upside: -48.63%
Danaher
Jul 23, 2025
Maintains: Buy
Price Target: $240 → $225
Current: $215.15
Upside: +4.58%
Mettler-Toledo International
May 20, 2025
Upgrades: Buy
Price Target: $1,530 → $1,350
Current: $1,428.90
Upside: -5.52%
May 9, 2025
Maintains: Buy
Price Target: $95 → $70
Current: $62.42
Upside: +12.14%
May 8, 2025
Maintains: Neutral
Price Target: $57 → $45
Current: $40.55
Upside: +10.97%
May 2, 2025
Maintains: Buy
Price Target: $355 → $310
Current: $313.63
Upside: -1.16%
May 2, 2025
Maintains: Buy
Price Target: $355 → $310
Current: $315.34
Upside: -1.69%
May 1, 2025
Upgrades: Buy
Price Target: $145 → $115
Current: $93.89
Upside: +22.48%
Apr 7, 2025
Maintains: Overweight
Price Target: $122 → $99
Current: $90.66
Upside: +9.20%
Jan 17, 2025
Downgrades: Neutral
Price Target: $29 → $25
Current: $11.74
Upside: +113.04%
Jan 17, 2025
Downgrades: Neutral
Price Target: $250 → $185
Current: $178.92
Upside: +3.40%
Oct 18, 2024
Maintains: Neutral
Price Target: $7 → $9
Current: $9.09
Upside: -0.99%
Dec 7, 2023
Initiates: Neutral
Price Target: $35
Current: $22.81
Upside: +53.44%
Aug 10, 2023
Maintains: Neutral
Price Target: $225 → $200
Current: $119.34
Upside: +67.59%
Aug 8, 2023
Maintains: Neutral
Price Target: $14 → $11
Current: $2.93
Upside: +275.43%
Aug 4, 2023
Reiterates: Outperform
Price Target: $70
Current: $202.65
Upside: -65.46%
Feb 15, 2023
Reiterates: Underperform
Price Target: $7
Current: $17.24
Upside: -59.38%
Aug 25, 2022
Initiates: Neutral
Price Target: $345
Current: $379.56
Upside: -9.11%
Aug 25, 2022
Initiates: Neutral
Price Target: $260
Current: $168.32
Upside: +54.47%
Feb 4, 2022
Maintains: Equal-Weight
Price Target: $160 → $145
Current: $176.71
Upside: -17.94%
Feb 3, 2022
Maintains: Overweight
Price Target: $95 → $90
Current: $74.22
Upside: +21.26%
Dec 14, 2021
Maintains: Equal-Weight
Price Target: $62 → $64
Current: $45.66
Upside: +39.40%
Dec 14, 2021
Maintains: Overweight
Price Target: $330 → $340
Current: $254.00
Upside: +33.86%
Aug 10, 2021
Initiates: Overweight
Price Target: $24
Current: $24.67
Upside: -2.72%
Aug 14, 2019
Maintains: Hold
Price Target: $45 → $35
Current: $6.74
Upside: +419.29%